Cargando…
Immune Checkpoint Inhibition as Primary Adjuvant Therapy for an IDH1-Mutant Anaplastic Astrocytoma in a Patient with CMMRD: A Case Report—Usage of Immune Checkpoint Inhibition in CMMRD
Constitutional mismatch repair deficiency (CMMRD) is a rare autosomal recessive hereditary cancer syndrome due to biallelic germline mutation involving one of the four DNA mismatch repair genes. Here we present a case of a young female with CMMRD, homozygous for the c.2002A>G mutation in the PMS2...
Autores principales: | Rittberg, Rebekah, Harlos, Craig, Rothenmund, Heidi, Das, Anirban, Tabori, Uri, Sinha, Namita, Singh, Harminder, Chodirker, Bernie, Kim, Christina A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985791/ https://www.ncbi.nlm.nih.gov/pubmed/33535600 http://dx.doi.org/10.3390/curroncol28010074 |
Ejemplares similares
-
Role of video capsule endoscopy in patients with constitutional mismatch repair deficiency (CMMRD) syndrome: report from the International CMMRD Consortium
por: Shimamura, Y., et al.
Publicado: (2018) -
Report of the fifth meeting of the European Consortium 'Care for CMMRD' (C4CMMRD), Leiden, The Netherlands, July 6th 2019
por: Suerink, M., et al.
Publicado: (2020) -
Recurrent posterior fossa group A (PFA) ependymoma in a young child with constitutional mismatch repair deficiency (CMMRD)
por: Briggs, Mayen, et al.
Publicado: (2022) -
CMMRD caused by PMS1 mutation in a sudanese consanguineous family
por: Hamad, Reem S., et al.
Publicado: (2022) -
HGG-40. NF1 mosaicism in a CMMRD-patient with a glioblastoma
por: Guerrini-Rousseau, Lea, et al.
Publicado: (2022)